Wall Street analysts expect that DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) will announce ($0.25) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for DelMar Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.39). DelMar Pharmaceuticals reported earnings per share of ($0.17) in the same quarter last year, which would suggest a negative year over year growth rate of 47.1%. The company is expected to announce its next quarterly earnings results on Tuesday, September 12th.
According to Zacks, analysts expect that DelMar Pharmaceuticals will report full-year earnings of ($0.83) per share for the current financial year, with EPS estimates ranging from ($0.97) to ($0.67). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.09) to ($0.69). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for DelMar Pharmaceuticals.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its earnings results on Thursday, May 18th. The company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18).
DMPI has been the topic of several analyst reports. Maxim Group set a $11.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, April 13th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of DelMar Pharmaceuticals in a report on Tuesday, May 30th.
ILLEGAL ACTIVITY WARNING: “DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) Expected to Announce Earnings of -$0.25 Per Share” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://stocknewstimes.com/2017/07/20/delmar-pharmaceuticals-inc-nasdaqdmpi-expected-to-announce-earnings-of-0-25-per-share.html.
DelMar Pharmaceuticals (NASDAQ DMPI) traded up 2.54% on Wednesday, hitting $2.02. 17,169 shares of the stock were exchanged. The company’s 50 day moving average price is $2.06 and its 200-day moving average price is $3.28. DelMar Pharmaceuticals has a one year low of $1.66 and a one year high of $8.15.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Get a free copy of the Zacks research report on DelMar Pharmaceuticals (DMPI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
